Sanjay Nayak, MBBS, PhD, was the founder and fund manager of a biotech-focused private investment fund, Sentiv Capital. The fund invested in public and private biotechnology companies and has been a sought-after co-investor, based on the quality and depth of his due diligence and contributions to investment strategy. Dr. Nayak’s investment approach integrated more than 20 years of expertise in retina and ophthalmology with strong connections spanning industry, the investment community and top key opinion leaders, as well as a unique strategic acuity related to healthcare markets. Prior to founding Sentiv Capital, Dr. Nayak was the founder and Managing Partner at AnalyzeRx LLC, a well-respected healthcare consulting practice focused on delivering customized, high-end, qualitative market analytics and competitive strategy to large-cap pharmaceutical and biotechnology companies.
The firm developed a differentiated perspective on retinal therapeutics and provided competitive analysis, strategic guidance and supported the business development needs of its clients for more than fifteen years. Prior to his work at Analyze Rx LLC, Dr. Nayak was a Director at Strategic Analysis, Healthcare, which was acquired by IMS Health. His consulting work was focused on pharmaceutical competitive analysis encompassing commercial launch preparations and regulatory, pipeline and clinical trial evaluations. Dr. Nayak received his medical degree (MBBS) from Grant Medical College, University of Bombay, India and earned a PhD in pharmacology from Drexel University, Philadelphia, Pennsylvania. He is the author or co-author on several publications related to presynaptic receptors in the brain.
What is Sanjay Nayak's net worth?
The estimated net worth of Sanjay Nayak is at least $2.70 million as of February 23rd, 2026. Nayak owns 330,653 shares of Ocular Therapeutix stock worth more than $2,704,742 as of March 22nd. This net worth approximation does not reflect any other assets that Nayak may own. Learn More about Sanjay Nayak's net worth.
How old is Sanjay Nayak?
Nayak is currently 54 years old. There are 3 older executives and no younger executives at Ocular Therapeutix. The oldest executive at Ocular Therapeutix is Dr. Peter K. Jarrett Ph.D., Chief Technology Officer, who is 67 years old. Learn More on Sanjay Nayak's age.
How do I contact Sanjay Nayak?
Has Sanjay Nayak been buying or selling shares of Ocular Therapeutix?
In the last ninety days, Sanjay Nayak has sold $108,110.44 of Ocular Therapeutix stock. Most recently, Sanjay Nayak sold 1,759 shares of the business's stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $8.28, for a transaction totalling $14,564.52. Following the completion of the sale, the insider now directly owns 330,653 shares of the company's stock, valued at $2,737,806.84. Learn More on Sanjay Nayak's trading history.
Who are Ocular Therapeutix's active insiders?
Are insiders buying or selling shares of Ocular Therapeutix?
During the last year, Ocular Therapeutix insiders bought shares 2 times. They purchased a total of 70,229 shares worth more than $530,954.14. During the last year, insiders at the biopharmaceutical company sold shares 23 times. They sold a total of 288,106 shares worth more than $2,691,191.43. The most recent insider tranaction occured on February, 23rd when insider Pravin Dugel sold 20,056 shares worth more than $166,063.68. Insiders at Ocular Therapeutix own 2.3% of the company.
Learn More about insider trades at Ocular Therapeutix. Information on this page was last updated on 2/23/2026.
